Rejuvenate Bio
Rejuvenate Bio is a biotechnology company focused on developing gene therapies to treat age-related diseases in humans and dogs. Their mission is to create treatments that address chronic, age-related conditions, leveraging innovative gene therapy approaches to extend healthspan and lifespan. They collaborate with academic institutions and industry partners to advance their scientific research and clinical programs.
Industries
Nr. of Employees
small (1-50)
Products
RJB-0402 (liver-directed gene therapy expressing FGF21)
A liver-directed gene therapy candidate designed to express the FGF21 protein to address metabolic and age-related disease biology; developed as a single-dose therapeutic intended to provide durable systemic exposure to the therapeutic protein.
Human-RJB-0402
Liver directed gene therapy delivering FGF21.
RJB-0402 (liver-directed gene therapy expressing FGF21)
A liver-directed gene therapy candidate designed to express the FGF21 protein to address metabolic and age-related disease biology; developed as a single-dose therapeutic intended to provide durable systemic exposure to the therapeutic protein.
Human-RJB-0402
Liver directed gene therapy delivering FGF21.
Services
On-site veterinary clinical trial recruiting dogs with staged valvular heart disease to evaluate safety and efficacy of a cardio-protective gene therapy; includes enrollment, staging, and outcome assessment performed at a veterinary medical center.
Collaborative development and commercialization arrangements with animal health companies to support product development, regulatory filing, and market introduction of veterinary gene therapy products.
On-site veterinary clinical trial recruiting dogs with staged valvular heart disease to evaluate safety and efficacy of a cardio-protective gene therapy; includes enrollment, staging, and outcome assessment performed at a veterinary medical center.
Collaborative development and commercialization arrangements with animal health companies to support product development, regulatory filing, and market introduction of veterinary gene therapy products.
Expertise Areas
- Gene therapy development
- Preclinical translational research
- Veterinary clinical trials and animal health development
- Aging biology and cellular reprogramming
Key Technologies
- Gene therapy
- AAV liver-tropic vector delivery
- Secreted protein expression via gene delivery
- Partial cellular reprogramming via transgene expression
News & Updates
The company announced new members Hugh Calkins, M.D., Stephen Chelko, Ph.D., and Dr. Elif Oral, M.D.
A collaboration to develop and commercialize a gene therapy for Mitral Valve Disease in dogs.
The company raised over $10 million in funding to advance gene therapy programs for aging-related conditions in humans and dogs.
Details about the development of gene therapy for Mitral Valve Disease in dogs.
Research hosted at Nature on cellular reprogramming for age reversal.
Published at the Proceedings of the National Academy of Sciences, demonstrating the potential of gene therapy to treat multiple age-related diseases.
The company announced new members Hugh Calkins, M.D., Stephen Chelko, Ph.D., and Dr. Elif Oral, M.D.
A collaboration to develop and commercialize a gene therapy for Mitral Valve Disease in dogs.
The company raised over $10 million in funding to advance gene therapy programs for aging-related conditions in humans and dogs.
Details about the development of gene therapy for Mitral Valve Disease in dogs.
Research hosted at Nature on cellular reprogramming for age reversal.
Published at the Proceedings of the National Academy of Sciences, demonstrating the potential of gene therapy to treat multiple age-related diseases.